GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.417
-0.052 (-11.14%)
At close: Mar 9, 2026, 4:00 PM EDT
0.437
+0.020 (4.80%)
After-hours: Mar 9, 2026, 7:17 PM EDT
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2024. The number of employees decreased by 1 or -50.00% compared to the previous year.
Employees
1
Change (1Y)
-1
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$34,449,000
Market Cap
13.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 34 |
| Quantum BioPharma | 17 |
| IN8bio | 17 |
| Serina Therapeutics | 13 |
| Cocrystal Pharma | 11 |
| Traws Pharma | 7 |
| Quoin Pharmaceuticals | 5 |
| Jupiter Neurosciences | 4 |
GTBP News
- 7 days ago - GT Biopharma Reports Full Year 2025 Financial Results - GlobeNewsWire
- 20 days ago - GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - GlobeNewsWire
- 4 weeks ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - GlobeNewsWire
- 7 weeks ago - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - GlobeNewsWire
- 7 weeks ago - EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
- 2 months ago - Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PRNewsWire
- 3 months ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 4 months ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire